No Data
China NT Pharma Reports Significant Losses for 2024
NT PHARMA (01011.HK) reported an annual loss of 53.4 million yuan.
On March 31, Gelonghui reported that NT PHARMA (01011.HK) announced that in 2023, the group completed a Business restructuring, transitioning from a heavy asset business to a light asset industry. By the year ending December 31, 2024, the group's overall revenue increased by 30.6 million yuan or 413.5% to 38 million yuan compared to 7.4 million yuan. The group recorded a loss of 53.4 million yuan for the year ending December 31, 2024, while the loss for the same period in 2023 was 143.6 million yuan, a year-on-year decrease of 62.8%.
NT PHARMA: ANNOUNCEMENT OF AUDITED ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024
The optimization policy direction for drug central purchasing is a hot topic: overcoming the "Low Stock Price" phenomenon and guiding quality supervision.
① The government work report on March 5 mentioned the need to "optimize the Pharmaceutical and consumables centralized procurement policy"; ② From the overall trend of optimizing the centralized procurement policy, there is a greater emphasis on moderate price reductions and quality supervision, and the concentration of the Industry is expected to further increase.
BD Trade resolves financing difficulties! Industry: Innovative Drugs have survived, but the challenge of thriving is even greater.
① In 2024, license-out Trade has become an important way for Biotech to recover funds and increase revenue; ② The quality and standing of Innovative Drugs in China are gaining more international recognition; ③ Whether Innovative Drugs are worth investing in is related to the secondary market in the short term, but in the medium to long term, it depends on the improvement of the primary market exit channels, the payment environment for Innovative Drugs, and other issues.
Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?
① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.
China NT Pharma Group Company Limited (HKG:1011) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough
